Apoptosis-regulated low-avidity cancer-specific CD8 T Cells Can Be Rescued to Eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice

Cancer Immunology Research

Volumn 2, Issue 4, 2014, Pages 307-319

  Black, Chelsea M ^a,b   Armstrong, Todd D ^a,b   Jaffee, Elizabeth M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; DIFFERENTIATION ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; FAS LIGAND; GAMMA INTERFERON; OX40IG; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASMS; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD24; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TUMOR ESCAPE;

EID: 84921433729     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0145     Document Type: Article

References (49)

1. Durrant LG, Spendlove I. Cancer vaccines entering phase III clinical trials. Expert Opin Emerg Drugs 2003; 8: 489-500.
2. Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol 2011; 186: 3847-57.
3. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000; 13: 829-40.
4. Kawai K, Ohashi PS. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 1995; 374: 68-9.
5. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996; 184: 485-92.
6. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005; 22: 275-84.
7. Redmond WL, Marincek BC, Sherman LA. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 2005; 174: 2046-53.
8. Mittendorf EA, Sharma P. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines 2010; 9: 89-105.
9. Hernandez J, Aung S, Redmond WL, Sherman LA. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med 2001; 194: 707-17.
10. + cytotoxic cells. J Immunol 2005; 174: 4098-104.
11. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
12. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-53.
13. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173: 945-54.
14. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, et al. High avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 2013; 73: 595-604.
15. + T cell tolerance and cancer immunotherapy. J Immunother 2003; 26: 1-11.
16. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-51.
17. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75.
18. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100: 4712-7.
19. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-50.
20. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-6.
21. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21: 624-30.
22. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neuexpressing tumors after depletion of effector/memory-like regulatory T cells. PLoS ONE 2012; 7: e31962.
23. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118: 499-509.
24. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201: 1591-602.
25. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003; 170: 4273-80.
26. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25: 230-7.
27. Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000; 164: 107-12.
28. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172: 4821-5.
29. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161: 6510-7.
30. Song J, So T, Cheng M, Tang X. Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005; 22: 621-31.
31. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective mmunity in Her-2/neu transgenic mice. Int J Cancer 2005; 116: 934-43.
32. Hombach AA, Chmielewski M, Rappl G, Abken H. Adoptive immunotherapy with redirected T cells produces CCR7(-) cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther 2013; 24: 259-69.
33. + T cell tolerance to an endogenous tumor antigen. J Immunol 2006; 176: 974-83.
34. Schwartz RH T cell anergy. Annu Rev Immunol 2003; 21: 305-34.
35. Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A. 4-1BB costimulation enhances human CD8(+) Tcell priming by augmenting the proliferation and survival of effector CD8(+)T cells. Int Immunol 2002; 14: 1155-67.
36. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-nduced cell death and enhances antitumor effectorfunction. J Immunother 2011; 34: 236-50.
37. + T cells that are reactive with alloantigens. PLoS ONE 2012; 7: e45481.
38. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11: 1062-70.
39. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4T cells. Immunity 2001; 15: 445-55.
40. Stagg J, Sharkey J, Pommey S, Young R, Takeda K, Yagita H, et al. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 2008; 105: 16254-9.
41. Hitsumoto Y, Song DS, Okada M, Hamada F, Saheki S, Takeuchi N. Enhancement of CD3-mediated thymocyte apoptosis by the cross-linkage of heat-stable antigen. Immunology 1996; 89: 200-4.
42. Jung KC, Park WS, Kim HJ, Choi EY, Kook MC, Lee HW, et al. TCR-independent and caspase-independent apoptosis of murine thymocytes by CD24 cross-linking. J Immunol 2004; 172: 795-802.
43. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166: 5567-77.
44. Kim JB, Ko E, Han W, Lee JE, Lee KM, Shin I, et al. CD24 cross-linking nduces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer 2008; 8: 118.
45. Green DR, Droin N, Pinkoski M. Activation-induced cell death in Tcells. Immunol Rev 2003; 193: 70-81.
46. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-4.
47. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373: 438-41.
48. Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R. Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 2009; 6: 15-25.
49. Mallone R, Kochik SA, Laughlin EM, Gersuk VH, Reijonen H, Kwok WW, et al. Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes 2004; 53: 971-7.